$TBRIF $THRM.V Therma Bright Ships Initial Venowav
Post# of 62

https://www.newsfilecorp.com/release/122007
Toronto, Ontario--(Newsfile Corp. - April 28, 2022) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"

Despite the challenges of material and component shortages, logistics and shipping delays and lockdowns in various parts of China, the initial order was completed and shipped recently.
Venowave is a compact and lightweight Deep Vein Thrombosis (DVT) prevention pump specifically designed for use at home. The Venowave device uses a continuous wave motion to increase blood flow in the veins. The increased blood circulation helps prevent venous stasis, which is a major contributor in thrombus formation. Specifically, the device imitates the body's venous system to counteract the pooling of blood in the lower extremities which can lead to clotting. With about 50% of DVTs beginning to form intra-operatively and 75% forming within 48 hours post-operatively, this technology is pioneering an alternative, easy to use life-saving treatment for this condition.
Rob Fia, CEO stated "We are pleased to have the first shipments of our Venowave product sent to DME Authority, our US distributor. It has been a frustrating process with all of the shortages and delays, but we are now poised to increase production and availability of the product as demand grows. We are excited to be able to deliver products to customers in the US who have been patiently waiting for this potential life saving technology."

